0001140361-24-008887.txt : 20240221
0001140361-24-008887.hdr.sgml : 20240221
20240221205422
ACCESSION NUMBER: 0001140361-24-008887
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240216
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: White Mark Andrew
CENTRAL INDEX KEY: 0001973240
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36829
FILM NUMBER: 24661988
MAIL ADDRESS:
STREET 1: C/O ROCKET PHARMACEUTICALS, INC.
STREET 2: 9 CEDARBROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001281895
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: 646-440-9100
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20040226
4
1
form4.xml
FORM 4
X0508
4
2024-02-16
0001281895
ROCKET PHARMACEUTICALS, INC.
RCKT
0001973240
White Mark Andrew
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE
CRANBURY
NJ
08512
true
Chief Medical Officer
false
Common Stock
2024-02-16
4
A
0
11096
0
A
87758
D
Stock Option (Right to Buy)
30.01
2024-02-16
4
A
0
32727
0
A
2034-02-16
Common Stock
32727
32727
D
Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years.
This option represents a right to purchase a total of 32,727 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
/s/ Martin Wilson, as attorney-in-fact for Mark Andrew White
2024-02-21